Trial Profile
Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Genentech
- 17 Nov 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 25 Jul 2007 New trial record.